UNSPSC 51313214: Bamipine salicylate

This classification denotes a histamine-1 receptor antagonist C19H24N2.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D7769LY0R, chemically known as benzoic acid, 2-hydroxy-, compd. with 1-methyl-n-phenyl-n-(phenylmethyl)-4-piperidinamine, but more generally known as bamipine salicylate, which bears US NIH Compound Identifier 6453348. European Medicines Agency schedules Bamipine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12982MIG.

Most nations, for tariff and trade purposes, schedule bamipine salicylate under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE SALICYLATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.C1CCC(C(C1)C(=O)O)O.

UNSPSC 51313214 Bamipine salicylate is a Commodity code that nominally covers a specific pharmaceutical ingredient, but recent state and local procurement activity under this code shows little alignment with the code's stated scope. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, a Texas Health and Human Services inquiry into direct-to-manufacturer prescription programs, and a Minnesota multistate cooperative purchasing contract for generic multi-source pharmaceuticals and OTC products — none of which directly address bamipine salicylate as a procured product. The code appears to capture broader pharmaceutical procurement activity rather than a discrete chemical ingredient, with issuing bodies spanning county health departments (Seminole County, Florida), state health commissions (Texas HHS), and multistate cooperative purchasing consortia (MMCAP administered by Minnesota Department of Administration). The geographic footprint includes Florida, Texas, Minnesota, and Oregon among recent solicitations.

Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida), the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products across multiple states with proposals due March 26, 2026. The MMCAP contract carries specific requirements including cGMP and Drug Supply Chain Security Act compliance, pricing through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers, and a 3 percent administrative fee on all purchases, with commercial general liability insurance of $5 million per occurrence. The code shows low decision-relevance for business development targeting bamipine salicylate as a discrete product line; procurement under this code reflects general pharmaceutical supply activity rather than a consistent commodity family.